XML 57 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Productivity Improvement And Restructuring Initiatives (Tables)
12 Months Ended
Dec. 31, 2017
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
Productivity improvement and restructuring related charges, including those relate to the discontinuation of the molecular diagnostics product line, recorded for the years ended December 31 by segment were as follows ($ in millions):
 
2017
 
2016
 
2015
Life Sciences
$
25.4

 
$
40.5

 
$
27.5

Diagnostics
85.4

 
62.2

 
33.6

Dental
35.8

 
34.3

 
25.3

Environmental & Applied Solutions
12.5

 
15.4

 
11.1

Total
$
159.1

 
$
152.4

 
$
97.5

The table below summarizes the Company’s accrual balance and utilization by type of productivity improvement and restructuring costs associated with the 2017 and 2016 actions ($ in millions):
 
Employee Severance and Related
 
Facility Exit and Related
 
Total
Balance, January 1, 2016
$
65.6

 
$
13.9

 
$
79.5

Costs incurred
111.0

 
41.4

 
152.4

Paid/settled
(131.3
)
 
(43.5
)
 
(174.8
)
Balance, December 31, 2016
45.3

 
11.8

 
57.1

Costs incurred
77.7

 
81.4

 
159.1

Paid/settled
(74.0
)
 
(75.9
)
 
(149.9
)
Balance, December 31, 2017
$
49.0

 
$
17.3

 
$
66.3

Schedule of Restructuring Reserve by Type of Cost
These charges are reflected in the following captions in the accompanying Consolidated Statements of Earnings ($ in millions):
 
2017
 
2016
 
2015
Cost of sales
$
38.0

 
$
25.4

 
$
31.9

Selling, general and administrative expenses
121.1

 
127.0

 
65.6

Total
$
159.1

 
$
152.4

 
$
97.5